This work was supported in part by a KAKENHI grant from the Japan Society for the Promotion of Science [grant numbers 23K13883] (M.M.) and the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP24ama121054 (M.A.)
A licensed provider can help determine which format fits your health profile and routine
RiskBenefit Perspective Despite theoretical concerns, the clinical reality is clear: GLP-1 therapies produce substantial weight loss Improve glycemic control and cardiometabolic outcomes Reduce cardiovascular risk in multiple studies When evaluating carcinogenicity risk, current evidence suggests: Strong rodent signals exist but may not translate to humans Long-term human data has not confirmed increased thyroid cancer risk Regulatory warnings remain precautionary rather than confirmatory Conclusion The GLP-1 receptor agonist classfrom Liraglutide to next-generation oral agents like Orforglipronrepresents one of the most transformative areas in metabolic medicine
Gut Microbes 7 (3), 189200
They modulate ROS levels, restore immune homeostasis, and remodel the local inflammatory microenvironment, either as monotherapy or in combination with conventional agents
While hes unsure how its accuracy and guidance compare to traditional lab tests and doctor visits, he still sees value for those wanting to take charge of their health
